Predictors of deferral of treatment for hepatitis C infection in Australian clinics

Medical Journal of Australia

Volumn 194, Issue 8, 2011, Pages 398-402

  Gidding, Heather F ^a   Law, Matthew G ^b   Amin, Janaki ^c   MacDonald, Graeme A ^d   Sasadeusz, Joe J ^e   Jones, Tracey L ^f   Strasser, Simone I ^g   George, Jacob ^g   Dore, Gregory J ^h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h Infectious Diseases Clinical Services Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DEPENDENCE; DRUG USE; FOLLOW UP; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL;

EID: 79955520725     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03029.x     Document Type: Article

References (27)

1. Gidding HF, Topp L, Middleton M, et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J Gast Hepatol 2009; 24: 1648-1654.
2. Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011; 11: 52.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
5. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
6. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2009.
7. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 Suppl 5: S313-S320.
8. Moirand R, Bilodeau M, Brissette S, Bruneau J. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol 2007; 21: 355-361.
9. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758.
10. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389.
11. Seal KH, Currie SL, Shen H, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol 2007; 41: 199-205.
12. S100 Pharmaceutical Benefits Scheme. In: Australian Government Department of Health and Ageing. National hepatitis C resource manual 2nd edition. Chapter 6. Treatments for hepatitis C. Canberra: DoHA, 2008. http://www.health.gov.au/internet/publications/publishing.nsf/Content/phd-hepc-manual-toc (accessed Mar 2011).
13. Centre for Epidemiology and Research. 2008 report on adult health from the New South Wales Population Health Survey. Sydney: NSW Department of Health, 2009.
14. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
15. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
16. Poordad F. Big changes are coming in hepatitis C. Curr Gastroenterol Rep 2010; 13: 72-77.
17. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
18. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in a community-based cohort in New South Wales, Australia. J Viral Hepat 2010; 18: e104-e116.
19. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88: 49-53.
20. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159-165.
21. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215-217.
22. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
23. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-443.
24. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-123.
25. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101: 2254-2262.
26. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-277.
27. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-520.